Baidu
map

第4个适应症!大冢抗精神病药物Abilify(阿立哌唑)获日本批准治疗儿童自闭症谱系障碍

2016-10-08 佚名 生物谷

日本药企大冢(Otsuka)近日宣布,该公司开发的抗精神病药物Abilify(阿立哌唑,aripiprazole)获日本监管批准,用于治疗儿童自闭症谱系障碍(Autism Spectrum Disorder,ASD)相关的烦躁易怒症状(irritability)。 此次批准,也是Abilify获批的第4个适应症。之前,Abilify已获批治疗:(1)精神分裂症;(2)I型双相情感障碍相关的躁

日本药企大冢(Otsuka)近日宣布,该公司开发的抗精神病药物Abilify(阿立哌唑,aripiprazole)获日本监管批准,用于治疗儿童自闭症谱系障碍(Autism Spectrum Disorder,ASD)相关的烦躁易怒症状(irritability)。

此次批准,也是Abilify获批的第4个适应症。之前,Abilify已获批治疗:(1)精神分裂症;(2)I型双相情感障碍相关的躁狂或混合性发作;(3)抗抑郁疗法治疗不佳的重度抑郁症的辅助治疗。

据报道,在日本大约有10万例自闭症患者,该病在某些情况下可表现为攻击行为、脾气爆发、自我伤害及其他行为症状。针对这些症状,目前很少有治疗方案。在美国,Abilify于2009年获批用于儿科患者治疗自闭症障碍相关的烦躁易怒症状。

阿立哌唑(aripiprazole)是一种新型高脂溶性喹林酮衍生物,其药理作用特点即是突触后多巴胺D2受体拮抗剂,又是突触前多巴胺D2受体激动剂,也有激动D1、D3、D4受体的作用;对5-HT 1A受体具有部分受体拮抗或激活的双重作用;对5-HT2A受体有完全拮抗的作用。该特点有别于第一代和非典型抗精神病药物,即第二代抗精神药物,故而被称为多巴胺系统稳定剂或第三代抗精神病药物。上世以来,临床上主要用于精神分裂症,分裂情感性精神病和其它精神病性障碍的治疗。

原始出处:

Antipsychotic ABILIFY Gains approval in Japan for the Additional Indication
of Irritability Associated with Pediatric Autism Spectrum Disorder


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
    2016-10-12 1e10c84am36(暂无匿称)

    好文章,受益

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
    2016-10-11 知难而进

    继续关注!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2009370, encodeId=f2d120093e06e, content=<a href='/topic/show?id=df47284508e' target=_blank style='color:#2F92EE;'>#儿童自闭症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28450, encryptionId=df47284508e, topicName=儿童自闭症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Mar 06 06:24:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146357, encodeId=88ef14635e4a, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Oct 12 09:39:05 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145699, encodeId=3bde145699a3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:31:09 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145698, encodeId=327c14569850, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:30:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294268, encodeId=b8e5129426878, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313113, encodeId=b36f13131131d, content=<a href='/topic/show?id=454286386a1' target=_blank style='color:#2F92EE;'>#自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86386, encryptionId=454286386a1, topicName=自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336732, encodeId=9fce1336e32d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401126, encodeId=1a811401126f5, content=<a href='/topic/show?id=f8a09e910a1' target=_blank style='color:#2F92EE;'>#阿立哌唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97910, encryptionId=f8a09e910a1, topicName=阿立哌唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7662296077, createdName=huhuaidong388, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513068, encodeId=214f1513068f6, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515580, encodeId=317d1515580a9, content=<a href='/topic/show?id=d5d2284519e' target=_blank style='color:#2F92EE;'>#儿童自闭症谱系障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28451, encryptionId=d5d2284519e, topicName=儿童自闭症谱系障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=080710833308, createdName=ms705947299214030, createdTime=Mon Oct 10 04:24:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

相关资讯

灵北和大冢重磅精神病药物Rexulti获美国FDA批准用于精神分裂症的维持治疗

丹麦药企灵北(H.Lundbeck)和日本药企大冢(Otsuka)近日联合宣布,美国食品和药物管理局(FDA)已批准扩大精神病新药Rexulti(brexpiprazole)的药物标签,用于精神分裂症成人患者的维持治疗。 Rexulti是一种每日一次的口服药物,由大冢发现,由灵北和大冢联合开发,该药于2015年7月获FDA批准Rexulti:(1)作为一种辅助药物用于重度抑郁症(MDD)成人

大冢及施维雅结直肠癌复方新药Lonsurf英国NICE批准

日本药企大冢(Otsuka)与法国合作伙伴施维雅(Servier)联合开发的抗癌复方新药Lonsurf(trifluridine/tipiracil,FTD/TPI)近日在英国监管方面传来喜讯。英国医疗成本监管机构——英国国家卫生与临床优化研究所(NICE)发布最终指南,支持将Lonsurf用于英格兰和威尔士国家卫生服务(NHS)系统,用于以往已接受过或不适合现有疗法(包括氟尿嘧啶、奥沙利铂或伊立

日本大冢公司血管加压素受体拮抗剂托伐普坦(苏麦卡)在中国上市

 2012年2月22日,选择性血管加压素(AVP)Ⅱ型受体(简称V2受体)拮抗剂托伐普坦(苏麦卡)上市会在上海召开。据悉,托伐普坦是全球范围内的首个血管加压素受体拮抗剂。此前,托伐普坦已获国家食品药品监督管理局(SFDA)正式批准,并开始在中国生产、销售。   血管加压素(AVP)又称抗利尿激素,在下丘脑合成,储存在垂体后叶,是调节人体水平衡最主要的激素。某些疾病会导致血管加压素水平异常增高,

大冢及Lundbeck长效版Abilify新药申请审批遭FDA推迟

FDA已推迟了长效版(每月一次)重磅抗精神病药物Abilify的新药审批申请。大冢(Otsuka)制药及合作者Lundbeck,今天公布了FDA回复给公司的完整回应函(CRL),称FDA在最近的检查中发现为生产该药提供无菌水的第三方供应商存在缺陷。 "大冢正在与第三方供应商共同努力,尽早解决这一问题,并计划与FDA进行进一步的讨论以决定下一步骤,"大冢在今天的一份声明中说道。Abilify为年销

Baidu
map
Baidu
map
Baidu
map